共 107 条
[1]
Anthony T(2007)Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction J Pain Symptom Manag 34 S49-S59
[2]
Baron T(2012)Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution Cancer Manag Res 4 159-169
[3]
Mercadante S(2004)Aggressive pharmacological treatment for reversing malignant bowel obstruction J Pain Symptom Manag 28 412-416
[4]
Green S(1994)The physiology of somatostatin and its synthetic analogue, octreotide Eur J Palliat Care 1 20-22
[5]
Chi D(2000)Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction Support Care Cancer 8 188-191
[6]
Cunningham J(2015)Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer World J Surg Oncol 13 50-34
[7]
Herbst A(2000)Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial J Pain Symptom Manag 19 23-1192
[8]
Smart E(2002)Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial Anticancer Res 22 1187-392
[9]
Krouse RS(2012)Octreotide for malignant bowel obstruction: twenty years after Crit Rev Oncol Hematol 83 388-486
[10]
Tuca A(1991)Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction J Pain Symptom Manag 6 484-2214